Newly launched Turing Pharmaceuticals to develop intranasal ketamine, Syntocinon

Several months after Retrophin announced that it would divest several of its pipeline products, including Syntocinon intranasal oxytocin and intranasal ketamine, to Turing Pharmaceuticals, the latter company has officially announced its launch. Turing Pharmaceuticals is headed by Martin Shkreli, who left Retrophin suddenly after reports of “stock trading irregularities.” Shkreli commented, “”Our goal is to . . . Read more

Sunovion initiates Phase 3 program for glycopyrrolate inhalation solution

A Phase 3 trial program of Sunovion Pharmaceutical’s SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD has begun enrolling patients, the company announced. The program includes three studies expected to enroll about 2,340 COPD patients. SUN-101 is delivered using PARI’s eFlow nebulizer system and, if approved, would be the first nebulized LAMA . . . Read more

Sales of Zomig nasal spray up in 2014

Prescriptions for Zomig nasal spray increased 23% in 2014 compared to 2013, Impax Laboratories said, helping to offset a major decrease in revenues for the Impax Pharmaceuticals division after the 2013 loss of exclusivity for Zomig tablets. Revenues dropped from $113.2 million in 2013 to $47 million for 2014. In the fourth quarter of 2014, . . . Read more